Jaguar Health and Viking Therapeutics fell in Wednesday morning trading for company-specific reasons rather than a broader biotechnology selloff. Jaguar Health was at $14.21, down 59%, while Viking Therapeutics was at $39.11, down 4%. The iShares Biotechnology ETF was down 0.1%, compared with a 0.44% decline for the SPDR S&P 500 ETF Trust. No verified company disclosure explained Jaguar’s move, making profit-taking after a major prior advance the likeliest explanation supported by the available figures; the stock remained up 9% over the past month. Viking, by contrast, reported positive top-line data from a maintenance trial of its obesity drug candidate and scheduled a special investor call, after its shares rose sharply Tuesday. Its Wednesday decline represented a partial pullback from that gain, while the stock remained up 14% over the month. Investors are watching whether Viking stabilizes as the trial results are assessed and whether Jaguar continues unwinding its recent run. The contrasting moves underscore the volatility of individual biotechnology stocks, particularly low-priced micro-caps, when the sector itself offers no shared catalyst.